Tucatinib was first approved by the FDA for the treatment of patients with HER2-positive advanced unresectable or metastatic breast cancer in combination with trastuzumab and capecitabine on April 17, 2020.
Oncology Drug Crash Course: Tucatinib and Trastuzumab for HER2+ CRC
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Subcutaneous Daratumumab in High-Risk Smoldering Myeloma
2
Frontline Vaccine/Pembro Yields PFS Benefit in Advanced Melanoma
3
APP-Led Quality Assurance Group Is Feasible, Identifies Safety Events
4
What an Oncology APP Should Know About Exercise in Cancer Care
5
